Insmed, Inc. (INSM)
126.66
+5.14
(+4.23%)
USD |
NASDAQ |
Sep 02, 16:00
126.66
0.00 (0.00%)
After-Hours: 17:53
Insmed Research and Development Expense (TTM) : 860.84M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 860.84M |
| March 31, 2026 | 828.00M |
| December 31, 2025 | 771.09M |
| September 30, 2025 | 695.91M |
| June 30, 2025 | 660.30M |
| March 31, 2025 | 629.86M |
| December 31, 2024 | 598.37M |
| September 30, 2024 | 555.67M |
| June 30, 2024 | 514.01M |
| March 31, 2024 | 564.23M |
| December 31, 2023 | 571.01M |
| September 30, 2023 | 558.74M |
| June 30, 2023 | 549.47M |
| March 31, 2023 | 441.03M |
| December 31, 2022 | 397.52M |
| September 30, 2022 | 349.11M |
| June 30, 2022 | 319.58M |
| March 31, 2022 | 295.71M |
| December 31, 2021 | 272.74M |
| September 30, 2021 | 264.21M |
| June 30, 2021 | 235.27M |
| March 31, 2021 | 206.36M |
| December 31, 2020 | 181.16M |
| September 30, 2020 | 145.97M |
| June 30, 2020 | 138.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 136.69M |
| December 31, 2019 | 131.71M |
| September 30, 2019 | 139.01M |
| June 30, 2019 | 144.20M |
| March 31, 2019 | 146.39M |
| December 31, 2018 | 145.28M |
| September 30, 2018 | 139.31M |
| June 30, 2018 | 126.44M |
| March 31, 2018 | 117.59M |
| December 31, 2017 | 109.75M |
| September 30, 2017 | 130.67M |
| June 30, 2017 | 127.43M |
| March 31, 2017 | 124.43M |
| December 31, 2016 | 122.72M |
| September 30, 2016 | 87.50M |
| June 30, 2016 | 83.28M |
| March 31, 2016 | 77.66M |
| December 31, 2015 | 74.28M |
| September 30, 2015 | 69.43M |
| June 30, 2015 | 65.41M |
| March 31, 2015 | 62.10M |
| December 31, 2014 | 56.29M |
| September 30, 2014 | 51.12M |
| June 30, 2014 | 48.01M |
| March 31, 2014 | 45.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Biogen, Inc. | 1.736B |
| Gilead Sciences, Inc. | 5.943B |
| Agios Pharmaceuticals, Inc. | 351.40M |